Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
2.
J Clin Microbiol ; 49(12): 4319-21, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21998414

RESUMEN

We tested the activities of rifampin (RIF) and rifaximin (RFX) against 180 Clostridium difficile clinical isolates selected from Canadian and Italian culture collections. MICs were determined by CLSI agar dilution for both drugs and by Etest for RIF. Sixteen of 85 Italian isolates (18.8%) showed high-level resistance to both rifamycins (MICs, >16 µg/ml), compared to 2 of 95 (2.1%) Canadian isolates. Two new rpoB mutations were identified in rifamycin-resistant isolates. RIF susceptibility by Etest correlated completely with susceptibility to both rifamycins determined by agar dilution.


Asunto(s)
Antibacterianos/farmacología , Clostridioides difficile/efectos de los fármacos , Clostridioides difficile/aislamiento & purificación , Farmacorresistencia Bacteriana , Rifamicinas/farmacología , Canadá , Clostridioides difficile/genética , ARN Polimerasas Dirigidas por ADN/genética , Humanos , Italia , Pruebas de Sensibilidad Microbiana/métodos , Mutación Missense
3.
J Clin Microbiol ; 49(6): 2230-8, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21508155

RESUMEN

Clostridium difficile is a common cause of infectious diarrhea in hospitalized patients. A severe and increased incidence of C. difficile infection (CDI) is associated predominantly with the NAP1 strain; however, the existence of other severe-disease-associated (SDA) strains and the extensive genetic diversity across C. difficile complicate reliable detection and diagnosis. Comparative genome analysis of 14 sequenced genomes, including those of a subset of NAP1 isolates, allowed the assessment of genetic diversity within and between strain types to identify DNA markers that are associated with severe disease. Comparative genome analysis of 14 isolates, including five publicly available strains, revealed that C. difficile has a core genome of 3.4 Mb, comprising ∼ 3,000 genes. Analysis of the core genome identified candidate DNA markers that were subsequently evaluated using a multistrain panel of 177 isolates, representing more than 50 pulsovars and 8 toxinotypes. A subset of 117 isolates from the panel had associated patient data that allowed assessment of an association between the DNA markers and severe CDI. We identified 20 candidate DNA markers for species-wide detection and 10,683 single nucleotide polymorphisms (SNPs) associated with the predominant SDA strain (NAP1). A species-wide detection candidate marker, the sspA gene, was found to be the same across 177 sequenced isolates and lacked significant similarity to those of other species. Candidate SNPs in genes CD1269 and CD1265 were found to associate more closely with disease severity than currently used diagnostic markers, as they were also present in the toxin A-negative and B-positive (A-B+) strain types. The genetic markers identified illustrate the potential of comparative genomics for the discovery of diagnostic DNA-based targets that are species specific or associated with multiple SDA strains.


Asunto(s)
Técnicas de Tipificación Bacteriana , Clostridioides difficile/clasificación , Clostridioides difficile/patogenicidad , Infecciones por Clostridium/microbiología , Marcadores Genéticos , Genoma Bacteriano , Polimorfismo de Nucleótido Simple , Adulto , Anciano , Clostridioides difficile/genética , Infecciones por Clostridium/patología , ADN Bacteriano/genética , Femenino , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Virulencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...